Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
CHINA OILFIELD
02883
5
CNOOC
00883
| (FY)Dec 31, 2025 | (Q6)Jun 30, 2025 | (FY)Dec 31, 2024 | (Q6)Jun 30, 2024 | (FY)Dec 31, 2023 | (Q6)Jun 30, 2023 | (FY)Dec 31, 2022 | (Q6)Jun 30, 2022 | (FY)Dec 31, 2021 | (Q6)Jun 30, 2021 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 269.94%1.99M | 478.31%960K | 226.67%539K | 1.22%166K | -78.20%165K | -78.34%164K | -88.42%757K | -21.06%757K | 8.30%6.54M | -61.06%959K |
| Operating income | 269.94%1.99M | 478.31%960K | 226.67%539K | 1.22%166K | -78.20%165K | -78.34%164K | -88.42%757K | -21.06%757K | 8.30%6.54M | -61.06%959K |
| Operating expenses | ||||||||||
| Gross profit | ||||||||||
| Administrative expenses | -10.01%-19.43M | -37.47%-10.02M | -33.52%-17.66M | -7.57%-7.29M | 29.13%-13.23M | 29.79%-6.78M | 10.88%-18.66M | 6.47%-9.65M | -9.19%-20.94M | -6.59%-10.32M |
| Profit from asset sales | ---7.41M | ---819K | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Revaluation surplus | -123.51%-4.08M | 80.22%-2.33M | 244.27%17.36M | -179.49%-11.79M | 87.81%-12.03M | 87.59%-4.22M | -102.56%-98.71M | -175.40%-33.98M | -765.25%-48.73M | 213.75%45.07M |
| -Changes in the fair value of financial assets | -123.51%-4.08M | 80.22%-2.33M | 244.27%17.36M | -179.49%-11.79M | 87.81%-12.03M | 87.59%-4.22M | -102.56%-98.71M | -175.40%-33.98M | -765.25%-48.73M | 213.75%45.07M |
| Impairment and provision | ---143.15M | ---14.44M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| -Other impairment is provision | ---143.15M | ---14.44M | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Special items of operating profit | -59.44%146K | ---- | --360K | --360K | ---- | ---- | 276.67%339K | --90K | -86.34%90K | ---- |
| Operating profit | -28,801.84%-171.92M | -43.65%-26.65M | 102.39%599K | -71.28%-18.55M | 78.42%-25.09M | 74.69%-10.83M | -84.44%-116.27M | -219.84%-42.79M | -248.05%-63.04M | 176.55%35.71M |
| Financing cost | 10.50%-179K | 0.00%-99K | 0.99%-200K | 1.00%-99K | 73.53%-202K | 74.42%-100K | 22.77%-763K | 30.05%-391K | -45.51%-988K | -107.04%-559K |
| Earning before tax | -43,233.58%-172.1M | -43.42%-26.75M | 101.58%399K | -70.62%-18.65M | 78.39%-25.29M | 74.69%-10.93M | -82.78%-117.04M | -222.85%-43.18M | -240.73%-64.03M | 174.92%35.15M |
| After-tax profit from continuing operations | -43,233.58%-172.1M | -43.42%-26.75M | 101.58%399K | -70.62%-18.65M | 78.39%-25.29M | 74.69%-10.93M | -82.78%-117.04M | -222.85%-43.18M | -240.73%-64.03M | 174.92%35.15M |
| Earning after tax | -43,233.58%-172.1M | -43.42%-26.75M | 101.58%399K | -70.62%-18.65M | 78.39%-25.29M | 74.69%-10.93M | -82.78%-117.04M | -222.85%-43.18M | -240.73%-64.03M | 174.92%35.15M |
| Profit attributable to shareholders | -43,233.58%-172.1M | -43.42%-26.75M | 101.58%399K | -70.62%-18.65M | 78.39%-25.29M | 74.69%-10.93M | -82.78%-117.04M | -222.85%-43.18M | -240.73%-64.03M | 174.92%35.15M |
| Basic earnings per share | -41,100.00%-0.164 | -12.83%-0.0255 | 101.23%0.0004 | -60.28%-0.0226 | 80.49%-0.0326 | 77.15%-0.0141 | -82.82%-0.1671 | -222.91%-0.0617 | -241.04%-0.0914 | 174.93%0.0502 |
| Diluted earnings per share | -41,100.00%-0.164 | -12.83%-0.0255 | 101.23%0.0004 | -60.28%-0.0226 | 80.49%-0.0326 | 77.15%-0.0141 | -82.82%-0.1671 | -222.91%-0.0617 | -241.04%-0.0914 | 174.93%0.0502 |
| Currency Unit | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD | HKD |
| Accounting Standards | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS | HKAS |
| Audit Opinions | -- | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- | Unqualified Opinion | -- |
| Auditor | -- | -- | Zhongzhi Xin (Hong Kong) Certified Public Accountants Limited | -- | Kaiyuan Xinde Certified Public Accountants Co., Ltd. | -- | Kaiyuan Xinde Certified Public Accountants Co., Ltd. | -- | National Health Accounting Firm Co., Ltd. | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.